MX2016004286A - Biomarcadores de cancer y usos de los mismos. - Google Patents
Biomarcadores de cancer y usos de los mismos.Info
- Publication number
- MX2016004286A MX2016004286A MX2016004286A MX2016004286A MX2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A MX 2016004286 A MX2016004286 A MX 2016004286A
- Authority
- MX
- Mexico
- Prior art keywords
- her2
- specific binding
- binding member
- domain
- cancer biomarkers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317622.7A GB201317622D0 (en) | 2013-10-04 | 2013-10-04 | Cancer biomarkers and uses thereof |
| PCT/GB2014/052994 WO2015049537A1 (en) | 2013-10-04 | 2014-10-03 | Cancer biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004286A true MX2016004286A (es) | 2017-01-18 |
Family
ID=49630223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004286A MX2016004286A (es) | 2013-10-04 | 2014-10-03 | Biomarcadores de cancer y usos de los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160289336A1 (https=) |
| EP (1) | EP3052647B1 (https=) |
| JP (1) | JP6449308B2 (https=) |
| KR (1) | KR20160092992A (https=) |
| CN (1) | CN105722997A (https=) |
| AU (1) | AU2014330942A1 (https=) |
| BR (1) | BR112016007348A2 (https=) |
| CA (1) | CA2925186A1 (https=) |
| CL (1) | CL2016000777A1 (https=) |
| DK (1) | DK3052647T3 (https=) |
| EA (1) | EA201690450A1 (https=) |
| ES (1) | ES2687783T3 (https=) |
| GB (1) | GB201317622D0 (https=) |
| HR (1) | HRP20181566T1 (https=) |
| IL (1) | IL244510A0 (https=) |
| LT (1) | LT3052647T (https=) |
| MX (1) | MX2016004286A (https=) |
| PE (1) | PE20160950A1 (https=) |
| SG (1) | SG11201602605TA (https=) |
| WO (1) | WO2015049537A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TW201642897A (zh) * | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3774902A1 (en) | 2018-04-02 | 2021-02-17 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| KR20210028155A (ko) * | 2018-05-17 | 2021-03-11 | 이뮤놈 인코포레이티드 | Ch3 도메인 에피토프 태그 |
| CN108875302B (zh) * | 2018-06-22 | 2022-02-22 | 广州漫瑞生物信息技术有限公司 | 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| KR102325731B1 (ko) * | 2020-01-15 | 2021-11-15 | 주식회사 베르티스 | 암의 진단용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103555733A (zh) * | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| EP3241842B1 (en) * | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| EP2435071A1 (en) * | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
-
2013
- 2013-10-04 GB GBGB1317622.7A patent/GB201317622D0/en not_active Ceased
-
2014
- 2014-10-03 LT LTEP14781645.8T patent/LT3052647T/lt unknown
- 2014-10-03 CA CA2925186A patent/CA2925186A1/en not_active Abandoned
- 2014-10-03 JP JP2016546183A patent/JP6449308B2/ja not_active Expired - Fee Related
- 2014-10-03 CN CN201480055024.5A patent/CN105722997A/zh active Pending
- 2014-10-03 WO PCT/GB2014/052994 patent/WO2015049537A1/en not_active Ceased
- 2014-10-03 EP EP14781645.8A patent/EP3052647B1/en active Active
- 2014-10-03 HR HRP20181566TT patent/HRP20181566T1/hr unknown
- 2014-10-03 ES ES14781645.8T patent/ES2687783T3/es active Active
- 2014-10-03 SG SG11201602605TA patent/SG11201602605TA/en unknown
- 2014-10-03 KR KR1020167011055A patent/KR20160092992A/ko not_active Withdrawn
- 2014-10-03 DK DK14781645.8T patent/DK3052647T3/en active
- 2014-10-03 EA EA201690450A patent/EA201690450A1/ru unknown
- 2014-10-03 PE PE2016000450A patent/PE20160950A1/es not_active Application Discontinuation
- 2014-10-03 BR BR112016007348A patent/BR112016007348A2/pt not_active Application Discontinuation
- 2014-10-03 AU AU2014330942A patent/AU2014330942A1/en not_active Abandoned
- 2014-10-03 MX MX2016004286A patent/MX2016004286A/es unknown
-
2016
- 2016-03-08 IL IL244510A patent/IL244510A0/en unknown
- 2016-03-31 US US15/087,272 patent/US20160289336A1/en not_active Abandoned
- 2016-04-04 CL CL2016000777A patent/CL2016000777A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20160950A1 (es) | 2016-10-02 |
| EA201690450A1 (ru) | 2016-10-31 |
| HK1221746A1 (en) | 2017-06-09 |
| JP2016533395A (ja) | 2016-10-27 |
| AU2014330942A1 (en) | 2016-05-19 |
| CL2016000777A1 (es) | 2017-02-17 |
| EP3052647B1 (en) | 2018-07-11 |
| BR112016007348A2 (pt) | 2018-01-23 |
| ES2687783T3 (es) | 2018-10-29 |
| EP3052647A1 (en) | 2016-08-10 |
| US20160289336A1 (en) | 2016-10-06 |
| CN105722997A (zh) | 2016-06-29 |
| IL244510A0 (en) | 2016-04-21 |
| LT3052647T (lt) | 2018-10-25 |
| JP6449308B2 (ja) | 2019-01-09 |
| CA2925186A1 (en) | 2015-04-09 |
| WO2015049537A1 (en) | 2015-04-09 |
| SG11201602605TA (en) | 2016-04-28 |
| KR20160092992A (ko) | 2016-08-05 |
| GB201317622D0 (en) | 2013-11-20 |
| HRP20181566T1 (hr) | 2018-11-30 |
| DK3052647T3 (en) | 2018-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004286A (es) | Biomarcadores de cancer y usos de los mismos. | |
| MX2016007885A (es) | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. | |
| NZ603271A (en) | Anti-erbb3 antibodies | |
| NZ720353A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| PH12018501473A1 (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| DK2766040T3 (da) | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie | |
| NZ611785A (en) | Anti-notch1 antibodies | |
| NZ601588A (en) | Methods for treating breast cancer | |
| PH12016500580A1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| IN2014DN09717A (https=) | ||
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| NZ625758A (en) | Method for treating breast cancer | |
| MX385284B (es) | Anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico (egfr) para usarse en el tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreático. |